Attachment III 
INFORMED CONSENT 
Study Title: A Phase One Study of Immunization with Gamma 
Interferon Transduced Neuroblastoma Cells 
Principal Investigators: (Robert C. Seeger, M.D., Co-Chairman, Children's 
Hospital, Lx)s Angeles; Joseph D. Rosen^tt, 
Co-Chairman, UCLA) 
Stephen Feig, M.D., Oncologist, UCLA 
Randal Wada, M.D., Oncologist, UCLA 
Introduction and Purpose 
I (my child/ward) hereby authorize Dr. Joseph Rosenblatt, M.D., Dr. Stephen Feig and Dr. 
Robert Seeger, M.D. and their associates 
to include me (my child/ward) in the research project entitled A Phase One Study of 
Immunization with Gamma Interferon Transduced Neuroblastoma Cells. 
I have been asked to participate in a research study which is designed to test the safety of 
administering neuroblastoma cells to me (my child/ward), that have been genetically engineered 
to express gamma interferon, a substance known to enhance the immune response in certain 
tumor models, and to see whether this treatment can provoke an effective anti-tumor immune 
response by increasing the ability of the immune system to recognize and destroy 
neuroblastoma cells. I (my child/ward) have been asked to enroll in this study because I (my 
child/ward) have neuroblastoma which has been treated by high dose chemotherapy and 
autologous bone marrow transplant but which still may have a significant likelihood of 
recurring, or, because the neuroblastoma has been treated with conventional therapy but this 
has failed to totally eradicate the tumor cells, and persistent or recurrent neuroblastoma is 
present. 
The aim of this phase I study is to determine the safety of administration of genetically 
engineered neuroblastoma cells when given as an injection under the skin, and to determine the 
maximum tolerated dose of such cells so that in future studies the doses required for maximum 
potential effect will be known. No effect of these tumor cell preparations has been 
demonstrated yet in human cancers. 
Recombinant DNA Research, Volume 19 
